North America epigenomics market is anticipated to rise at a CAGR of 17.51% during the forecast period of 2018-2026. The presence of a large number of biotech and pharmaceutical manufacturers gives an edge to this region as compared to other regional markets. The report presents a detailed analysis of geographies such as the US and Canada for the North America epigenomics market.

NORTH AMERICA EPIGENOMICS MARKET 2018-2026

North America Epigenomics Market by Product (Reagents, Kits, Instruments, Enzymes, Services) by Technology (Dna Methylation, Histone Methylation & Acetylation, Microrna Modification) by Application (Oncology, Non-oncology) by Application Area (Diagnosis, Drug Discovery, Therapy Optimization, Prognosis) by Segment (Epigenetic Diagnosis(Cancer, Neuro, Inflammatory & Autoimmune Disease, R&d, Personalized Medicine, Neurological Disorders, Cvd, Others), Epigenetic Therapies(Biomarkers, Noncoding Rnas, Mirnas, Chromatin Remodeling)) by Geography.

Request free sample

North America epigenomics market is anticipated to rise at a CAGR of 17.51% during the forecast period of 2018-2026. The presence of a large number of biotech and pharmaceutical manufacturers gives an edge to this region as compared to other regional markets.

The report presents a detailed analysis of geographies such as the US and Canada for the North America epigenomics market. The US has witnessed a high prevalence of cancer in the last few years.  Other disorders like cardiovascular and neurological diseases have also seen a considerable rise in this region. As a combined result of all these factors, the epigenomics market demand has witnessed a significant rise in this region.

Leading market players in this region include Merck Sharp & Dohme, Roche Holding Ag, Glaxosmithkline, Naturewise Biotech & Medicals Corp, Johnson & Johnson, Abbott Laboratories, Rubicon Genomics, Epigentek, Astellas Pharmaceuticals, Epigenomics Ag, Agilent Technologies, Affymetrix, Novartis Pharma Ag, Bayer Ag, Orchid Chemicals & Pharmaceuticals Limited, Celgene Corp, and Illumina Inc.

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP-DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • ASIA PACIFIC IS ANTICIPATED TO BE THE MOST DYNAMIC REGIONAL MARKET
        • REAGENTS FORMS A MAJOR PART OF EPIGENOMIC MARKET BY PRODUCT
        • EPIGENETICS DIAGNOSIS IS A MAJOR PART OF EPIGENOMIC MARKET, AND PERSONALIZED MEDICINES IS SHOWING A DYNAMIC GROWTH
        • ONCOLOGY IS THE PRIMARY APPLICATION WHILE NON-ONCOLOGY IS SHOWING A BETTER GROWTH
    1. MARKET DYNAMICS
      • MARKET DEFINITION & SCOPE
      • MARKET DRIVERS
        • ADVANCEMENT IN THE PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES
        • RISE IN THE AGEING POPULATION
        • DECLINE IN THE SEQUENCING COSTS AND TIME
        • ESCALATION IN FUNDING FOR RESEARCH & DEVELOPMENT
        • NEED FOR BETTER CANCER THERAPIES
        • GROWTH IN PERSONALIZED MEDICINE
        • INCREASING IMPORTANCE OF EPIGENETIC TECHNOLOGY
      • MARKET RESTRAINTS
        • INEFFICIENCY IN IDENTIFICATION AND VALIDATION OF BIOMARKER
        • PRESENCE OF COMPLEX REGULATORY FRAMEWORK
        • LACK OF REIMBURSEMENT PROVISION IN INSURANCE FOR EPIGENOMIC
      • MARKET OPPORTUNITIES
        • INCREASING AWARENESS ABOUT EPIGENOMIC
        • ADVANCEMENT OF POTENTIAL IN EMERGING MARKETS
        • EXPANDING APPLICATIONS OF EPIGENETICS IN PERSONALIZED MEDICINE AND TARGETED THERAPY
        • USE OF EPIGENOMIC IN NON-ONCOLOGY APPLICATIONS
      • MARKET CHALLENGES
        • SCARCITY OF TRAINED PROFESSIONALS
        • HIGH COST OF INSTRUMENTS AND CONSUMABLES
    1. MARKET BY PRODUCT
      • REAGENTS
      • KITS
      • INSTRUMENTS
      • ENZYMES
      • SERVICES
    2. MARKET BY TECHNOLOGY
      • DNA METHYLATION
      • HISTONE METHYLATION & ACETYLATION
      • MICRORNA MODIFICATION
    3. MARKET BY APPLICATION
      • ONCOLOGY
        • DNA METHYLTRANSFERASE INHIBITORS
        • HISTONE DEACETYLASE INHIBITORS
      • NON-ONCOLOGY
    4. MARKET BY APPLICATION AREA
      • DIAGNOSIS
      • DRUG DISCOVERY
      • THERAPY OPTIMIZATION
      • PROGNOSIS
    5. MARKET BY SEGMENT
      • EPIGENETIC DIAGNOSIS
        • CANCER
        • NEURO
          • MENTAL RETARDATION
          • ALZHEIMER’S DISEASE
          • DEPRESSION
          • OTHER
        • CARDIOVASCULAR
          • VASCULAR DISEASE
          • HEART FAILURE
          • OTHERS
        • INFLAMMATORY & AUTOIMMUNE DISEASE
          • RHEUMATOID ARTHRITIS
          • DIABETES
          • LUPUS
          • MULTIPLE SCLEROSIS
          • INFLAMMATORY BOWEL DISEASES
        • R&D
          • DNA METHYLATION IN CANCER DETECTION
          • IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION
          • MECHANISMS OF EPIGENETIC GENE SILENCING
        • PERSONALIZED MEDICINE
          • CANCER TREATMENT
            • LUNG CANCER
            • SOLID CANCERS
            • GASTRIC CANCER
            • HAEMATOLOGICAL CANCERS
            • OTHERS
          • NEUROLOGICAL DISORDERS
            • MENTAL RETARDATION
            • HUNTINGTON’S DISEASE
            • PARKINSON’S DISEASE
            • ALZHEIMER’S DISEASE
            • DEPRESSION
          • CVD
          • OTHERS
            • RHEUMATOID ARTHRITIS
            • DIABETES
            • MYELODYSPLASTIC SYNDROMES
            • MULTIPLE SCLEROSIS
            • OBESITY
            • INFLAMMATORY BOWEL DISEASES
            • LUPUS
            • OTHER
      • EPIGENETIC THERAPIES
        • BIOMARKERS
          • DNA METHYLATION FOR CANCER DETECTION
          • HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION
            • HISTONE METHYLATION
            • HISTONE ACETYLATION
          • NONCODING RNAS
          • MIRNAS
          • CHROMATIN REMODELING
    1. KEY ANALYTICS
      • PORTER’S FIVE FORCE MODEL
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE
        • BARGAINING POWER OF SUPPLIERS
        • BARGAINING POWER OF BUYERS
        • THREAT OF COMPETITIVE RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
    2. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • UNITED STATES
        • CANADA
    1. COMPANY PROFILES
      • ABBOTT LABORATORIES
      • AFFYMETRIX
      • AGILENT TECHNOLOGIES
      • ASTELLAS PHARMACEUTICALS
      • BAYER AG
      • BIO VISION
      • CELGENE CORP.
      • EPIGENOMICS AG
      • GLAXOSMITHKLINE
      • ILLUMINA INC.
      • JOHNSON & JOHNSON
      • MERCK SHARP & DOHME
      • NATUREWISE BIOTECH & MEDICALS CORP.
      • NOVARTIS PHARMA AG
      • ORCHID CHEMICALS & PHARMACEUTICALS LIMITED
      • TBG DIAGNOSTICS LIMITED
      • RUBICON GENOMICS
      • ROCHE HOLDING AG

    LIST OF TABLES

    TABLE 1 NORTH AMERICA EPIGENOMIC MARKET, BY COUNTRY, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 2 NORTH AMERICA EPIGENOMIC MARKET, BY PRODUCT, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 3 NORTH AMERICA EPIGENOMIC MARKET, BY TECHNOLOGY, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 4 NORTH AMERICA EPIGENOMIC MARKET, BY APPLICATION, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 5 NORTH AMERICA EPIGENOMIC MARKET, BY APPLICATION AREA, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 6 NORTH AMERICA EPIGENOMIC MARKET, BY SEGMENT, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 7 NORTH AMERICA EPIGENOMIC MARKET, BY EPIGENETIC DIAGNOSIS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 8 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY NEURO, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 9 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY CARDIOVASCULAR, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 10 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY INFLAMMATORY & AUTOIMMUNE DISEASE, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 11 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY R&D, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 12 NORTH AMERICA EPIGENOMIC MARKET, BY PERSONALIZED MEDICINE, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 13 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY CANCER TREATMENT, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 14 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY NEUROLOGICAL DISORDERS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 15 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY OTHERS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 16 NORTH AMERICA EPIGENOMICS MARKET, BY BIOMARKERS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 17 OPPORTUNITY MATRIX

    TABLE 18 VENDOR LANDSCAPE

    TABLE 19 NORTH AMERICA EPIGENOMIC MARKET, BY COUNTRY, 2018-2026 (IN $ TEN THOUSAND)

     

    LIST OF FIGURES

    TABLE 1 NORTH AMERICA EPIGENOMIC MARKET, BY COUNTRY, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 2 NORTH AMERICA EPIGENOMIC MARKET, BY PRODUCT, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 3 NORTH AMERICA EPIGENOMIC MARKET, BY TECHNOLOGY, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 4 NORTH AMERICA EPIGENOMIC MARKET, BY APPLICATION, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 5 NORTH AMERICA EPIGENOMIC MARKET, BY APPLICATION AREA, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 6 NORTH AMERICA EPIGENOMIC MARKET, BY SEGMENT, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 7 NORTH AMERICA EPIGENOMIC MARKET, BY EPIGENETIC DIAGNOSIS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 8 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY NEURO, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 9 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY CARDIOVASCULAR, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 10 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY INFLAMMATORY & AUTOIMMUNE DISEASE, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 11 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY R&D, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 12 NORTH AMERICA EPIGENOMIC MARKET, BY PERSONALIZED MEDICINE, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 13 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY CANCER TREATMENT, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 14 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY NEUROLOGICAL DISORDERS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 15 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY OTHERS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 16 NORTH AMERICA EPIGENOMICS MARKET, BY BIOMARKERS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 17 OPPORTUNITY MATRIX

    TABLE 18 VENDOR LANDSCAPE

    TABLE 19 NORTH AMERICA EPIGENOMIC MARKET, BY COUNTRY, 2018-2026 (IN $ TEN THOUSAND)

    1. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • UNITED STATES
        • CANADA
    1. MARKET BY PRODUCT
      • REAGENTS
      • KITS
      • INSTRUMENTS
      • ENZYMES
      • SERVICES
    2. MARKET BY TECHNOLOGY
      • DNA METHYLATION
      • HISTONE METHYLATION & ACETYLATION
      • MICRORNA MODIFICATION
    3. MARKET BY APPLICATION
      • ONCOLOGY
        • DNA METHYLTRANSFERASE INHIBITORS
        • HISTONE DEACETYLASE INHIBITORS
      • NON-ONCOLOGY
    4. MARKET BY APPLICATION AREA
      • DIAGNOSIS
      • DRUG DISCOVERY
      • THERAPY OPTIMIZATION
      • PROGNOSIS
    5. MARKET BY SEGMENT
      • EPIGENETIC DIAGNOSIS
        • CANCER
        • NEURO
          • MENTAL RETARDATION
          • ALZHEIMER’S DISEASE
          • DEPRESSION
          • OTHER
        • CARDIOVASCULAR
          • VASCULAR DISEASE
          • HEART FAILURE
          • OTHERS
        • INFLAMMATORY & AUTOIMMUNE DISEASE
          • RHEUMATOID ARTHRITIS
          • DIABETES
          • LUPUS
          • MULTIPLE SCLEROSIS
          • INFLAMMATORY BOWEL DISEASES
        • R&D
          • DNA METHYLATION IN CANCER DETECTION
          • IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION
          • MECHANISMS OF EPIGENETIC GENE SILENCING
        • PERSONALIZED MEDICINE
          • CANCER TREATMENT
            • LUNG CANCER
            • SOLID CANCERS
            • GASTRIC CANCER
            • HAEMATOLOGICAL CANCERS
            • OTHERS
          • NEUROLOGICAL DISORDERS
            • MENTAL RETARDATION
            • HUNTINGTON’S DISEASE
            • PARKINSON’S DISEASE
            • ALZHEIMER’S DISEASE
            • DEPRESSION
          • CVD
          • OTHERS
            • RHEUMATOID ARTHRITIS
            • DIABETES
            • MYELODYSPLASTIC SYNDROMES
            • MULTIPLE SCLEROSIS
            • OBESITY
            • INFLAMMATORY BOWEL DISEASES
            • LUPUS
            • OTHER
      • EPIGENETIC THERAPIES
        • BIOMARKERS
          • DNA METHYLATION FOR CANCER DETECTION
          • HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION
            • HISTONE METHYLATION
            • HISTONE ACETYLATION
          • NONCODING RNAS
          • MIRNAS
          • CHROMATIN REMODELING

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type